Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for COVID-19 PEP or Preemptive Therapy
NCT04308668Phase 3Completed
- Sponsor
- University of Minnesota
- Start
- Mar 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19), sponsored by University of Minnesota. Started Mar 2020; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04308668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308668.